Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This study is divided into 2 parts: a phase 1b portion (part 1) and a phase 2 portion (part 2). Part 1: The primary objective of part 1 is to identify a tolerable dose of AMG 655 in combination with panitumumab based on the incidence of dose-limiting toxicities (DLTs) in subjects with metastatic colorectal cancer (mCRC). Part 2: The primary objective of part 2 is to evaluate stratified by KRAS status (wild-type versus mutant) the objective response rate (ORR) in subjects with mCRC treated with the combination of panitumumab and AMG 655 (tolerable dose identified in part 1).
Critère d'inclusion
- Colorectal cancer (CRC)